Orchard Therapeutics plc Gains 97.4%

Orchard Therapeutics plc (ORTX:NASDAQ) rocketted at $15.95, representing a gain of 97.4%. On Thu, Oct 05, 2023, ORTX:NASDAQ touched a New 2-Week High of $15.95. The stock got featured on our News Catalysts scanner on Thu, Oct 05, 2023 at 01:10 PM in the 'MISCELLANEOUS' category. From Thu, Sep 21, 2023, the stock recorded 60.00% Up Days and 45.45% Green Days

About Orchard Therapeutics plc (ORTX:NASDAQ)

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Its gene therapy approach seeks to transform a patient's own, or autologous, HSCs into a gene-modified drug product to treat the patient's disease through a single administration. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.